These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
371 related articles for article (PubMed ID: 15156345)
1. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors. Warren K; Gervais A; Aikin A; Egorin M; Balis FM Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345 [TBL] [Abstract][Full Text] [Related]
2. Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors. Warren KE; Patel MC; Aikin AA; Widemann B; Libucha M; Adamson PC; Neuwirth R; Benziger D; O'Toole T; Ford K; Patronas N; Packer RJ; Balis FM Cancer Chemother Pharmacol; 2001 Oct; 48(4):275-82. PubMed ID: 11710627 [TBL] [Abstract][Full Text] [Related]
3. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours. Veal GJ; Errington J; Tilby MJ; Pearson AD; Foot AB; McDowell H; Ellershaw C; Pizer B; Nowell GM; Pearson DG; Boddy AV; Br J Cancer; 2007 Mar; 96(5):725-31. PubMed ID: 17299395 [TBL] [Abstract][Full Text] [Related]
4. Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group. Warren K; Jakacki R; Widemann B; Aikin A; Libucha M; Packer R; Vezina G; Reaman G; Shaw D; Krailo M; Osborne C; Cehelsky J; Caldwell D; Stanwood J; Steinberg SM; Balis FM Cancer Chemother Pharmacol; 2006 Sep; 58(3):343-7. PubMed ID: 16408203 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours. Thomas HD; Lind MJ; Ford J; Bleehen N; Calvert AH; Boddy AV Cancer Chemother Pharmacol; 2000; 45(4):284-90. PubMed ID: 10755316 [TBL] [Abstract][Full Text] [Related]
6. Carboplatin pharmacokinetics in young children with brain tumors. Tonda ME; Heideman RL; Petros WP; Friedman HS; Murry DJ; Rodman JH Cancer Chemother Pharmacol; 1996; 38(5):395-400. PubMed ID: 8765431 [TBL] [Abstract][Full Text] [Related]
7. Enhanced delivery of carboplatin into brain tumours with intravenous Cereport (RMP-7): dramatic differences and insight gained from dosing parameters. Emerich DF; Snodgrass P; Dean R; Agostino M; Hasler B; Pink M; Xiong H; Kim BS; Bartus RT Br J Cancer; 1999 Jun; 80(7):964-70. PubMed ID: 10362103 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. Obasaju CK; Johnson SW; Rogatko A; Kilpatrick D; Brennan JM; Hamilton TC; Ozols RF; O'Dwyer PJ; Gallo JM Clin Cancer Res; 1996 Mar; 2(3):549-52. PubMed ID: 9816202 [TBL] [Abstract][Full Text] [Related]
9. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer. Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659 [TBL] [Abstract][Full Text] [Related]
10. Flat dosing of carboplatin is justified in adult patients with normal renal function. Ekhart C; de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH Clin Cancer Res; 2006 Nov; 12(21):6502-8. PubMed ID: 17085665 [TBL] [Abstract][Full Text] [Related]
11. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study. Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574 [TBL] [Abstract][Full Text] [Related]
12. Intravenous cereport (RMP-7) modifies topographic uptake profile of carboplatin within rat glioma and brain surrounding tumor, elevates platinum levels, and enhances survival. Bartus RT; Snodgrass P; Marsh J; Agostino M; Perkins A; Emerich DF J Pharmacol Exp Ther; 2000 Jun; 293(3):903-11. PubMed ID: 10869391 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. Oguri T; Shimokata T; Inada M; Ito I; Ando Y; Sasaki Y; Hasegawa Y Cancer Chemother Pharmacol; 2010 Sep; 66(4):813-7. PubMed ID: 20563583 [TBL] [Abstract][Full Text] [Related]
14. Dose-banding of carboplatin: rationale and proposed banding scheme. Kaestner S; Sewell G J Oncol Pharm Pract; 2007 Jun; 13(2):109-17. PubMed ID: 17873111 [TBL] [Abstract][Full Text] [Related]
15. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin. De Jonge ME; Mathôt RA; Van Dam SM; Beijnen JH; Rodenhuis S Cancer Chemother Pharmacol; 2002 Sep; 50(3):251-5. PubMed ID: 12203108 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of serum iohexol clearance for use in predicting carboplatin clearance in cats. Bailey DB; Rassnick KM; Prey JD; Dykes NL Am J Vet Res; 2009 Sep; 70(9):1135-40. PubMed ID: 19719430 [TBL] [Abstract][Full Text] [Related]
17. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae. Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776 [TBL] [Abstract][Full Text] [Related]
18. A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignancies. Plummer R; Woll P; Fyfe D; Boddy AV; Griffin M; Hewitt P; Carmichael J; Namouni F; Cohen M; Verrill M Clin Cancer Res; 2008 Dec; 14(24):8288-94. PubMed ID: 19088046 [TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of carboplatin in children. Chatelut E; Boddy AV; Peng B; Rubie H; Lavit M; Dezeuze A; Pearson AD; Roché H; Robert A; Newell DR; Canal P Clin Pharmacol Ther; 1996 Apr; 59(4):436-43. PubMed ID: 8612389 [TBL] [Abstract][Full Text] [Related]
20. Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption. Neuwelt EA; Gilmer-Knight K; Lacy C; Nicholson HS; Kraemer DF; Doolittle ND; Hornig GW; Muldoon LL Pediatr Blood Cancer; 2006 Aug; 47(2):174-82. PubMed ID: 16086410 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]